Scholarlink

Background <p>Multiple myeloma (MM) is an incurable malignancy, marked by treatment resistance and frequent relapses, posing ongoing challenges to patients’ long-term management. Herein, we have examined tRNA-derived small RNA fragments (3′U-tRFs), generated from precursor tRNAs, to identify MM-related 3′U-tRFs in ameliorating MM precision prognostics.</p> Methods <p>3′U-tRF profiles were generated by small RNA-seq data. Target prediction and gene ontology analysis were assessed by tRFtarget and DAVID databases, respectively. CD138 + 3′U-tRF<sup>SerTGA</sup> levels were quantified in our MM screening cohort (<i>n</i> = 136 patients) by RT-qPCR. Kaplan–Meier and Cox proportional regression analyses were performed, using disease progression and patients’ mortality as clinical endpoints. Internal validation was conducted by bootstrap Cox regression while clinical benefit on patients’ prognosis was assessed by decision curve analysis (DCA).</p> Results <p>Small RNA-seq data analysis highlighted the significantly increased 3′U-tRF<sup>SerTGA</sup> levels in MM cell lines compared to normal cells (FC: 14.03). Our screening cohort confirmed the significantly higher risk for short-term progression and worse survival of the patients presenting elevated 3′U-tRF<sup>SerTGA</sup>. 3′U-tRF<sup>SerTGA</sup>-fitted multivariate models demonstrated superior risk-stratification of the patients for treatment response and prognosis.</p> Conclusions <p>Our study indicate the elevated 3′U-tRF<sup>SerTGA</sup> as a strong independent predictor of poor first-line chemotherapy outcomes and MM progression, providing refined stratification of patient risk.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRFSerTGA leads to poor disease prognosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月4日

查看全文
  • Konstantinos Soureas,
  • Panagiotis Malandrakis,
  • Maria-Alexandra Papadimitriou,
  • Ioannis Ntanasis-Stathopoulos,
  • Katerina-Marina Pilala,
  • Christine-Ivy Liacos,
  • Maria Gavriatopoulou,
  • Efstathios Kastritis,
  • Meletios-Athanasios Dimopoulos,
  • Andreas Scorilas,
  • Evangelos Terpos,
  • Margaritis Avgeris

摘要

Background

Multiple myeloma (MM) is an incurable malignancy, marked by treatment resistance and frequent relapses, posing ongoing challenges to patients’ long-term management. Herein, we have examined tRNA-derived small RNA fragments (3′U-tRFs), generated from precursor tRNAs, to identify MM-related 3′U-tRFs in ameliorating MM precision prognostics.

Methods

3′U-tRF profiles were generated by small RNA-seq data. Target prediction and gene ontology analysis were assessed by tRFtarget and DAVID databases, respectively. CD138 + 3′U-tRFSerTGA levels were quantified in our MM screening cohort (n = 136 patients) by RT-qPCR. Kaplan–Meier and Cox proportional regression analyses were performed, using disease progression and patients’ mortality as clinical endpoints. Internal validation was conducted by bootstrap Cox regression while clinical benefit on patients’ prognosis was assessed by decision curve analysis (DCA).

Results

Small RNA-seq data analysis highlighted the significantly increased 3′U-tRFSerTGA levels in MM cell lines compared to normal cells (FC: 14.03). Our screening cohort confirmed the significantly higher risk for short-term progression and worse survival of the patients presenting elevated 3′U-tRFSerTGA. 3′U-tRFSerTGA-fitted multivariate models demonstrated superior risk-stratification of the patients for treatment response and prognosis.

Conclusions

Our study indicate the elevated 3′U-tRFSerTGA as a strong independent predictor of poor first-line chemotherapy outcomes and MM progression, providing refined stratification of patient risk.